Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Author(s): Ciliberto Domenico, Ierardi Antonella, Caroleo Benedetto, Scalise Luigi, Cimellaro Antonio, Colangelo Lidia, Spaziano Giuseppe and Luca Gallelli *

Volume 14, Issue 3, 2019

Page: [233 - 237] Pages: 5

DOI: 10.2174/1574886314666190522094713

Abstract

Background: Panitumumab is an EGFR inhibitor used for the treatment of metastatic colorectal cancer (mCRC), even if its use is related to skin toxicity.

Case Presentation: We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5- fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC.

Results: In both patients, clinical, laboratory and radiological evaluation documented the presence of a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation and antimicrobial + corticosteroid treatment induced a remission of skin manifestations.

Conclusion: We reported for the first time the development of panniculitis during Panitumumab treatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or oxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with mCRC, without the development of adverse drug reactions or drug-drug interactions.

Keywords: Panitumumab, panniculitis, adverse drug reaction, EGFR, mCRC, FOLFOX.

« Previous Next »
Graphical Abstract

[1]
Ra HS, Shin SJ, Kim JH, Lim H, Cho BC, Roh MR. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol 2013; 27(1): e53-9.
[2]
Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 2013; 14(4): 327-33.
[3]
Thaler J, Karthaus M, Mineur L, et al. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 2012; 12: 438.
[4]
Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369(11): 1023-34.
[5]
Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32(21): 2240-7.
[6]
Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4(2): 107-19.
[7]
Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 2009; 43(10): 1658-66.
[8]
Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-47.
[9]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[10]
Mumoli L, Gambardella A, Labate A, et al. Rosacea-like facial rash related to metformin administration in a young woman. BMC Pharmacol Toxicol 2014; 15: 3.
[11]
Succurro E, Ruffo M, De Sarro G, Gallelli L, Arturi F. Bilateral lower limbs edema with “wooden” character induced by insulin glargine treatment. Acta Diabetol 2015; 52(4): 809-11.
[12]
Misago N, Inoue T, Narisawa Y. Delayed reaction after an octopus bite showing a giant cell-rich granulomatous dermatitis/panniculitis. J Cutan Pathol 2008; 35(11): 1068-72.
[13]
Vasapollo P, Cione E, Luciani F, Gallelli L. Generalized intense pruritus during Canagliflozin treatment: Is it an adverse drug reaction? Curr Drug Saf 2018; 13(1): 38-40.
[14]
Gallelli L, Ferraro M, Mauro GF, De Sarro G. Generalized exfoliative dermatitis induced by interferon alfa. Ann Pharmacother 2004; 38(12): 2173-4.
[15]
Bergman H, Walton T, Del Bel R, et al. Managing skin toxicities related to panitumumab. J Am Acad Dermatol 2014; 71(4): 754-9.
[16]
Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol 2015; 2(4): e1004969.
[17]
Reck M, Gutzmer R. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Onkologie 2010; 33(8-9): 470-9.
[18]
Liu Y, Jiang X, Gu Y, Chen Y. Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor. Int Immunopharmacol 2019; 69: 79-87.
[19]
Gallelli L, Ferreri G, Colosimo M, et al. Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy. Pharm Res 2003; 47: 493-9.
[20]
Gallelli L, Siniscalchi A, Palleria C, et al. Adverse Drug Reactions Related to drug administration in hospitalized patients. Curr Drug Saf 2017; 12(3): 171-7.
[21]
Caroleo B, Staltari O, Gallelli L, Perticone F. Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: Drug interactions or low adherence? BMJ Case Reports 2015; 2015.
[22]
Gallelli L, Staltari O, Palleria C, De Sarro G, Ferraro M. Hepatotoxicity induced by methimazole in a previously health patient. Curr Drug Saf 2009; 4: 204-6.
[23]
Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19(8): 1079-95.
[24]
Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011; 50(2): 129-46.
[25]
Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10: 345-56.
[26]
Arbitrio M, Di Martino MT, Barbieri V, et al. Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis. Cancer Chemother Pharmacol 2016; 77: 205-9.

Rights & Permissions Print Cite
Article Metrics
35
3
1
1
© 2024 Bentham Science Publishers | Privacy Policy